Real-World Effectiveness and Safety of Dupilumab for the Treatment of Moderate to Severe Atopic Dermatitis in Indian Patients: A Multi Centric Retrospective Study

INTRODUCTION: Treatment of moderate to severe atopic dermatitis (AD) is a real challenge for the dermatologists. Dupilumab is the first targeted biologic therapy approved for the treatment of children and adults with moderate-to-severe AD. The efficacy and safety of dupilumab in Indian patients is l...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhar, Sandipan, De, Abhishek, Srinivas, Sahana M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375526/
https://www.ncbi.nlm.nih.gov/pubmed/34446954
http://dx.doi.org/10.4103/ijd.ijd_860_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375526/
https://www.ncbi.nlm.nih.gov/pubmed/34446954
http://dx.doi.org/10.4103/ijd.ijd_860_20

Ejemplares similares